Cell and gene therapies: How can their promise be realized?
As a result, the services required to develop them are in more demand than ever.
BioPharma-Reporter, in a webinar on December 1, 2021, will take a look at some of the promising therapies in development, and what is needed to ensure reliable, consistent and scalable manufacturing so that the price of these treatments can be reduced and they can become mainstream.
Don’t miss out, register now for this free to access, online event.
We’ve assembled a great group of experts, both UK and US based speakers, for this webinar.
Joining use will be Matthew Durdy, chief executive and part of the founding team of the UK based Cell and Gene Therapy (CGT) Catapult.
He is credited with leading the design and implementation of the commercial model for the CGT Catapult’s manufacturing center and being a global champion for the early integration of healthcare economics and reimbursement expertise into decision-making and clinical product design.
Durdy's presentation will focus on how the CGT Catapult is helping the UK sector to grow, how it creates assets and capabilities that the UK cell and gene industry can reach into and utilize in order to overcome development obstacles.
Addressing bottlenecks
Also participating will be Sanjay Srivastava, managing director, CGT center of excellence, Accenture.
A senior management consultant with over 20 years of life sciences and health care experience, Srivastava is driving Accenture’s cell and gene therapy consulting practice.
He will outline how the current capacity of the CGT ecosystem is unable to keep up with the clinical and commercial products coming to market and what needs to be done to address gaps and bottlenecks in the supply chain.
Hear him as he speaks about the importance of industry standardization.
And, finally, the audience will get the manufacturer’s perspective.
Dr Arun Upadhyay, VP of research and development, at US developer, Ocugen, has over 15 years of experience from discovery research to early-stage clinical trials. He has worked extensively in drug development, from small molecules to biologics, and advanced cell and gene therapy modalities. In his current role, he is leading a team of scientists that is exploring how gene modifier therapeutic technology can transform the treatment of degenerative diseases.
Dr Upadhyay will talk about the broad challenges that exist at every stage of the development process for Ocugen’s gene therapy product candidates, and the importance of establishing strategic partnerships to secure hard-to-find manufacturing capacity and expertise for gene therapy product development.
Join us on December 1 as we discuss current challenges in this innovative field with the three specialists.
